SCHEMBL7516149

SCHEMBL7516149

Cc1cc2nc(-c3ccc(C=C4SC(=O)NC4=O)cc3)[nH]c2cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 8/20 0.51
PIM2 Q9P1W9 7/20 0.51
HPGD P15428 2/20 0.51
HPSE Q9Y251 1/20 0.50
CISD1 Q9NZ45 3/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
MAOB P27338 2/20 0.47
PIK3CD O00329 1/20 0.47
CSNK2A2 P19784 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
MTOR P42345 1/20 0.47
PIK3CG P48736 1/20 0.47
CLK1 P49759 1/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A1 P68400 1/20 0.47
DYRK1A Q13627 1/20 0.47
DYRK2 Q92630 1/20 0.47
DYRK1B Q9Y463 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7516143 1.00 PIM1 (0.51) PIM1PIM2HPGDHPSECISD1
SCHEMBL7516825 0.86 IGF1R (0.56) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7511802 0.86 PIM1 (0.51) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7516823 0.86 IGF1R (0.56) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7511794 0.86 PIM1 (0.51) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7511829 0.81 PIM1 (0.56) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7511827 0.81 PIM1 (0.56) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7521930 0.80 PIM1 (0.60) PIM1PIM2CISD1
SCHEMBL7511020 0.80 TDP1 (0.47) PIM1PIM2HPGDCISD1RAB9A
SCHEMBL7521926 0.80 PIM1 (0.60) PIM1PIM2CISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 PIM1 1545/4885PIM2 2078/4885HPGD 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.